Trobix Bio develops microbiome-based oncology therapeutics and a proprietary platform that engineers phages as medicines to precisely reprogram targeted gut bacteria for durable therapeutic effects. The company's platform converges computational, synthetic, and synthetic biology technologies to create orally administered cancer supportive‑care products. Its lead program, TBX201, is an oral capsule designed to specifically alter the gut microbiome to reduce the incidence and severity of severe diarrhea caused by irinotecan, a first-line chemotherapy used in over 100,000 patients annually. Trobix aims to reduce life‑threatening gastrointestinal toxicities and enable physicians to complete oncology treatments at optimal doses while improving patient quality of life. Led by CEO Dr. Adi Elkeles, the company intends to use new funding to advance development of its products and proprietary platform technology addressing gastrointestinal side effects of oncology treatments and other microbiome‑impacted GI diseases. Trobix Innovation is a preclinical biotechnology company led by Founder & CEO Dr. Adi Elkeles that develops therapies aimed at removing the threat of antimicrobial resistance. The company leverages its ActiSense™ and GoTrap™ technologies to create phage-based products that deliver DNA to a wide range of bacterial pathogens and actively sensitize them to antibiotics. Its lead product, TBX101, is designed to treat patients carrying gut antimicrobial-resistant bacteria and to restore an antibiotic-sensitive gut microbiome. Trobix intends to use the proceeds from its recent financing to advance its antimicrobial-resistance platform technology and to further pre-clinical development of TBX101. The company is based in Netanya, Israel and operates at the preclinical development stage.

Total raised

$6M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2023